Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs)
4 affiliations
- 1Department of Internal Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia. [email protected]
- 2Division of Endocrinology, Hospital Universitario Fundacion Santa Fe, Bogotá, Colombia. [email protected]
- 3Department of Internal Medicine, Hospital Universitario San Ignacio, Bogotá, Colombia
- 4Department of Internal Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia
Abstract
INTRODUCTION: The impact of GLP-1 receptor agonists (GLP1-RA) treatment on lean mass and body composition in patients with obesity is not fully understood. METHODOLOGY: Systematic review and meta-analysis of RCTs including patients with obesity treated with GLP1-RA at obesity doses, compared with placebo. Search was conducted in PubMed, Embase, and LILACS in March 2025. A meta-analysis was performed using a random-effects model to evaluate the change in lean mass as a proportion of total weight, the absolute and relative changes in lean mass, and adverse effects. RESULTS: Seven studies (821 patients) were included in the analysis. GLP1-RA significantly improved lean mass as a proportion of total weight, with an observed increase of 1.81% (95% CI: 1.1- 2.52; p < 0.00001; I² = 7%). However, a significant decrease was observed in the absolute change in lean mass (-1.74 kg; 95% CI: -3.04 to -0.45; p < 0.00001; I² = 98%) and in the percentage of lean mass (-3.06%; 95% CI: -5.10 to -1.02; p < 0.00001; I² = 98%). Semaglutide demonstrated the most significant reduction in absolute lean mass, with a loss of -5.44 kg (95% CI: -7.07 to -3.81; p < 0.00001). CONCLUSIONS: There is an improvement in body composition due to an increase in lean mass as a proportion of total weight, an effect that could be amplified with the use of semaglutide. Our results suggest that lean mass loss should not be considered a limitation for the use of these drugs in patients with obesity. However, it is essential to accompany drug treatment with nutritional and physical exercise interventions to preserve or improve muscle mass and optimize clinical outcomes.
Related
- GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: protocol for a systematic review and meta-analysis of randomized controlled trials
- Impact of GLP-1 Receptor Agonists on Cognitive Performance in Adults at Risk of Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Gonadotropin-releasing hormone antagonists versus agonists for endometriosis: a systematic review and meta-analysis of randomized controlled trials
- GLP-1 Receptor Agonists (GLP-1RAs) for treatment of tobacco and alcohol dependence: a systematic review and meta-analysis of randomised controlled trials
- GLP-1 Receptor Agonists, Stroke, and Cognitive Outcomes: Systematic Review and Meta-Regression
BibTeX
@article{jimenez2026effect,
title = {{Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs)}},
author = {L Jimenez and Óscar Múñoz and Diana Alfonso and Ana María Gómez Medina},
journal = {International Journal of Obesity},
year = {2026},
month = jun,
doi = {10.1038/s41366-026-02118-y},
url = {https://doi.org/10.1038/s41366-026-02118-y},
note = {CC BY},
}
RIS
TY - JOUR
TI - Effect of GLP-1 receptor agonists at doses for obesity management on muscle health: systematic review and meta-analysis of randomized controlled trials (RCTs)
AU - L Jimenez
AU - Óscar Múñoz
AU - Diana Alfonso
AU - Ana María Gómez Medina
PY - 2026
DA - 2026/06/19
JO - International Journal of Obesity
DO - 10.1038/s41366-026-02118-y
UR - https://doi.org/10.1038/s41366-026-02118-y
AB - INTRODUCTION: The impact of GLP-1 receptor agonists (GLP1-RA) treatment on lean mass and body composition in patients with obesity is not fully understood. METHODOLOGY: Systematic review and meta-analysis of RCTs including patients with obesity treated with GLP1-RA at obesity doses, compared with placebo. Search was conducted in PubMed, Embase, and LILACS in March 2025. A meta-analysis was performed using a random-effects model to evaluate the change in lean mass as a proportion of total weight, the absolute and relative changes in lean mass, and adverse effects. RESULTS: Seven studies (821 patients) were included in the analysis. GLP1-RA significantly improved lean mass as a proportion of total weight, with an observed increase of 1.81% (95% CI: 1.1- 2.52; p < 0.00001; I² = 7%). However, a significant decrease was observed in the absolute change in lean mass (-1.74 kg; 95% CI: -3.04 to -0.45; p < 0.00001; I² = 98%) and in the percentage of lean mass (-3.06%; 95% CI: -5.10 to -1.02; p < 0.00001; I² = 98%). Semaglutide demonstrated the most significant reduction in absolute lean mass, with a loss of -5.44 kg (95% CI: -7.07 to -3.81; p < 0.00001). CONCLUSIONS: There is an improvement in body composition due to an increase in lean mass as a proportion of total weight, an effect that could be amplified with the use of semaglutide. Our results suggest that lean mass loss should not be considered a limitation for the use of these drugs in patients with obesity. However, it is essential to accompany drug treatment with nutritional and physical exercise interventions to preserve or improve muscle mass and optimize clinical outcomes.
SN - 0307-0565
SN - 1476-5497
ER -